The Weight Loss Podcast

Discussing the rapid changes happening in the GLP-1 market. An update on everything we know so far.

Discussion on the Ethics of Access, especially for lower income populations looking for weight loss solutions, and the economic feasibility of long-term access for many.

Today we discuss how the election of Donald J. Trump to the white house as the 47th president of the United States impacts all the stuff we talk about on this podcast: Big Pharma, Weight Loss, GLP1 Medications, Regulations. We also talk about his team: Vivek Ramaswamy, Elon Musk, and others.

Let's really do a deep dive on the mechanisms of GLP1 that we haven't touched on previously. This is going to be a discussion for our long-time followers since we skip past a lot of introductory stuff.

Discussion about all the latest gossip on weight loss from around the country.

Discussing the FDAs recent reversal on compounding Terzepitide while they re-evaluate the shortage situation. This and more on today's episode.

You don't want to miss this episode! Today, we're looking into GLP1 pricing and how congress is putting BigPharma on the hotseat trying to understand why their drugs cost so much. All that and more on today's episode.

Today we discuss a major development: Novo Nordisk, the company behind WeGovy and Ozempic, is pushing the FDA to stop compounding pharmacies from manufacturing the compounded medications, citing the complexity of manufacture. Critics say it is just a ploy to secure profits.

Today we're going to do a deep dive into our sponsor and look at the services they offer and how they differ from other services in this space.

Discussion on a fascinating aspect of GLP1s that we are just beginning to understand. Today, we discuss the role of GLP1s in eliminating addiction!

Discuss the past week in the news. Talking about GLP1s, Big Pharma, Novartis Pivot Strategy, Unexpected Benefits of GLP1s, the real surprise: GLP1s reduces suicide risk in young adults, and more!

A discussion on the ten most common mistakes people make when they take these GLP-1 medications.

Let's find out what goes into making GLP1s and unravel a little of the mystery behind these medications which seem to be in short supply.

We're talking Semaglutide folks! A favorite topic amongst our listeners. So, here we go...

Today it's all about insurance - reviewing some of the challenges & opportunities for expanding coverage in the industry and talking about the state of things.

Let's discuss some success stories and talk about the importance of thorough documentation, collaboration with healthcare providers, understanding the appeals process, persistence, and utilizing available resources such as patient advocacy groups and copay assistance programs.

We discuss an important topic: What do you do when you are denied coverage for your weight loss medications? Well, we talk about some concrete steps people should look into.

Discussion around weight loss drugs and the possibility of employer coverage. Exciting times ahead! Not many employers cover these drugs today, but could that change? Also, what is the impact of these drugs on the federal budget for Medicare? All these and more on this episode.